Skip to main content
Premium Trial:

Request an Annual Quote

Burnham Institute Becomes NCI Chemical Biology Center

NEW YORK (GenomeWeb news) – The Burnham Institute for Medical Research will conduct research on oncology drug targets and cancer biology as part of efforts to develop personalized medical approaches to cancer for the National Cancer Institute, Burnham said on Monday.

NCI has named Burnham a Comprehensive Center in its Chemical Biology Consortium, which is a network of molecular oncologists, chemical biologists, and chemical screening centers, and it will conduct the work at the Burnham campuses in La Jolla, Calif., and in Orlando, Fla.

"The Chemical Biology Consortium gives Burnham an additional platform to use our advanced technologies, some of which are virtually unprecedented in the not-for-profit research world," Burnham CEO and President John Reed said in a statement.

Last year, Burnham won a $98 million grant to serve as a comprehensive national screening center for the National Institute of Health's Molecular Libraries Probe Production Centers Network, and it also recently received $10 million from the philanthropist Conrad Prebys for its Center for Chemical Genomics.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.